Last reviewed · How we verify
LNS8801
At a glance
| Generic name | LNS8801 |
|---|---|
| Sponsor | Linnaeus Therapeutics, Inc. |
| Modality | Biologic |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Study Assessing MTD, Safety, Tolerability, PK and Anti-tumor Effects of LNS8801alone and With Pembrolizumab (PHASE1, PHASE2)
- A Trial of LNS8801 With or Without Pembrolizumab in Patients With Refractory Melanoma (PHASE2, PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- LNS8801 CI brief — competitive landscape report
- LNS8801 updates RSS · CI watch RSS
- Linnaeus Therapeutics, Inc. portfolio CI